Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-κB activity

Fenofibrate: A New Treatment for Diabetic Retinopathy. Molecular Mechanisms and Future Perspectives

(2013) Rafael Simo et al.   CURRENT MEDICINAL CHEMISTRY

Pathogenic role of diabetes-induced PPAR-  down-regulation in microvascular dysfunction

(2013) Y. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Implications of the PPARs in the Diabetic Eye

(2013) Andreea Ciudin et al.   PPAR Research

Fenofibrate – A Potential Systemic Treatment for Diabetic Retinopathy?

(2012) Tien Yin Wong et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models

(2012) Ying Chen et al.   DIABETES

Global Prevalence and Major Risk Factors of Diabetic Retinopathy

(2012) J. W. Y. Yau et al.   DIABETES CARE

Usefulness of the Vitreous Fluid Analysis in the Translational Research of Diabetic Retinopathy

(2012) Olga Simó-Servat et al.   MEDIATORS OF INFLAMMATION

Alterations to the Blood–Retinal Barrier in Diabetes: Cytokines and Reactive Oxygen Species

(2011) Tiffany Frey et al.   ANTIOXIDANTS & REDOX SIGNALING

Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation

(2011) M. Villarroel et al.   DIABETOLOGIA

Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions

(2011) Soledad Miranda et al.   JOURNAL OF CELLULAR PHYSIOLOGY

AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan

(2011) Antero Salminen et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Placental Growth Factor Contributes to Micro-Vascular Abnormalization and Blood-Retinal Barrier Breakdown in Diabetic Retinopathy

(2011) Laura Kowalczuk et al.   PLoS One

Blood-Retinal Barrier

(2010) José Cunha-Vaz et al.   EUROPEAN JOURNAL OF OPHTHALMOLOGY

Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome

(2010) Renata Belfort et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate–activated protein kinase activation

(2010) Atsuko Tomizawa et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

PPARα activator fenofibrate modulates angiotensin II-induced inflammatory responses in vascular smooth muscle cells via the TLR4-dependent signaling pathway

(2009) Yuan-Yuan Ji et al.   BIOCHEMICAL PHARMACOLOGY

Effects of high glucose concentration on the barrier function and the expression of tight junction proteins in human retinal pigment epithelial cells

(2009) Marta Villarroel et al.   EXPERIMENTAL EYE RESEARCH

PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation

(2008) Toshie Okayasu et al.   LIFE SCIENCES